| pubmed-article:7648281 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:7648281 | lifeskim:mentions | umls-concept:C0019704 | lld:lifeskim |
| pubmed-article:7648281 | lifeskim:mentions | umls-concept:C0039195 | lld:lifeskim |
| pubmed-article:7648281 | lifeskim:mentions | umls-concept:C0033684 | lld:lifeskim |
| pubmed-article:7648281 | lifeskim:mentions | umls-concept:C0042210 | lld:lifeskim |
| pubmed-article:7648281 | lifeskim:mentions | umls-concept:C1414406 | lld:lifeskim |
| pubmed-article:7648281 | pubmed:issue | 1 | lld:pubmed |
| pubmed-article:7648281 | pubmed:dateCreated | 1995-9-28 | lld:pubmed |
| pubmed-article:7648281 | pubmed:abstractText | Cytotoxic T lymphocytes (CTL) play an important role in the immune response to viral infection by recognizing and destroying infected cells. HIV-1 elicits an unusually strong CTL response in infected individuals and clearance of the viremia of acute infection coincides with the development of HIV-specific CTL. Because HIV-specific CTL may provide protection against de novo viral infection, we compared the CTL response in seronegative volunteers treated with two vaccination approaches. Seven volunteers were immunized with a live recombinant vaccinia virus expressing the HIV envelope protein gp160LAI (HIVAC-1e) and boosted with 640 micrograms recombinant baculovirus-expressed gp160LAI in alum 1-13 months later. In a second study, three volunteers underwent four successive immunizations with 640 micrograms subunit gp160LAI in alum at 0, 1, 6, and 12 months. The first vaccination strategy using a liver vector would be expected to generate gp160-specific CTL, while for the second, using only whole-protein subunit, the generation of specific CTL would be unlikely. Predominantly CD8+ T-cell lines generated from PBMC by nonspecific stimulation with PHA and IL-2 were screened after three to four weeks of culture for cytolytic activity against autologous targets infected with vaccinia vectors encoding envLAI, RT, gag, and lacZ control. A strong gp 160-specific CTL response was detected in two vaccines in the recombinant vaccinia plus subunit boost study. Modest responses were seen in four of the other five live vector-primed vaccinees. No significant gp160-specific CTL were observed in three volunteers given only subunit rgp160 or in five control subjects. | lld:pubmed |
| pubmed-article:7648281 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7648281 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7648281 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7648281 | pubmed:language | eng | lld:pubmed |
| pubmed-article:7648281 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7648281 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:7648281 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7648281 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7648281 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7648281 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7648281 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7648281 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7648281 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:7648281 | pubmed:month | Sep | lld:pubmed |
| pubmed-article:7648281 | pubmed:issn | 1077-9450 | lld:pubmed |
| pubmed-article:7648281 | pubmed:author | pubmed-author:LiebermanJJ | lld:pubmed |
| pubmed-article:7648281 | pubmed:author | pubmed-author:SchwartzD HDH | lld:pubmed |
| pubmed-article:7648281 | pubmed:author | pubmed-author:PeralesM AMA | lld:pubmed |
| pubmed-article:7648281 | pubmed:author | pubmed-author:FabryJ AJA | lld:pubmed |
| pubmed-article:7648281 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:7648281 | pubmed:day | 1 | lld:pubmed |
| pubmed-article:7648281 | pubmed:volume | 10 | lld:pubmed |
| pubmed-article:7648281 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:7648281 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:7648281 | pubmed:pagination | 27-35 | lld:pubmed |
| pubmed-article:7648281 | pubmed:dateRevised | 2007-11-14 | lld:pubmed |
| pubmed-article:7648281 | pubmed:meshHeading | pubmed-meshheading:7648281-... | lld:pubmed |
| pubmed-article:7648281 | pubmed:meshHeading | pubmed-meshheading:7648281-... | lld:pubmed |
| pubmed-article:7648281 | pubmed:meshHeading | pubmed-meshheading:7648281-... | lld:pubmed |
| pubmed-article:7648281 | pubmed:meshHeading | pubmed-meshheading:7648281-... | lld:pubmed |
| pubmed-article:7648281 | pubmed:meshHeading | pubmed-meshheading:7648281-... | lld:pubmed |
| pubmed-article:7648281 | pubmed:meshHeading | pubmed-meshheading:7648281-... | lld:pubmed |
| pubmed-article:7648281 | pubmed:meshHeading | pubmed-meshheading:7648281-... | lld:pubmed |
| pubmed-article:7648281 | pubmed:meshHeading | pubmed-meshheading:7648281-... | lld:pubmed |
| pubmed-article:7648281 | pubmed:meshHeading | pubmed-meshheading:7648281-... | lld:pubmed |
| pubmed-article:7648281 | pubmed:meshHeading | pubmed-meshheading:7648281-... | lld:pubmed |
| pubmed-article:7648281 | pubmed:meshHeading | pubmed-meshheading:7648281-... | lld:pubmed |
| pubmed-article:7648281 | pubmed:meshHeading | pubmed-meshheading:7648281-... | lld:pubmed |
| pubmed-article:7648281 | pubmed:meshHeading | pubmed-meshheading:7648281-... | lld:pubmed |
| pubmed-article:7648281 | pubmed:meshHeading | pubmed-meshheading:7648281-... | lld:pubmed |
| pubmed-article:7648281 | pubmed:meshHeading | pubmed-meshheading:7648281-... | lld:pubmed |
| pubmed-article:7648281 | pubmed:year | 1995 | lld:pubmed |
| pubmed-article:7648281 | pubmed:articleTitle | A vaccinia-gp160-based vaccine but not a gp160 protein vaccine elicits anti-gp160 cytotoxic T lymphocytes in some HIV-1 seronegative vaccinees. | lld:pubmed |
| pubmed-article:7648281 | pubmed:affiliation | Department of Medicine, New England Medical Center, Boston, MA, USA. | lld:pubmed |
| pubmed-article:7648281 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:7648281 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:7648281 | pubmed:publicationType | Comparative Study | lld:pubmed |
| pubmed-article:7648281 | pubmed:publicationType | Research Support, U.S. Gov't, P.H.S. | lld:pubmed |
| pubmed-article:7648281 | pubmed:publicationType | Randomized Controlled Trial | lld:pubmed |
| pubmed-article:7648281 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| pubmed-article:7648281 | pubmed:publicationType | Multicenter Study | lld:pubmed |
| pubmed-article:7648281 | pubmed:publicationType | Clinical Trial, Phase I | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:7648281 | lld:pubmed |
